New drug holds promise to block clots in people with artery disease

DALLAS, April 30 The first study of a new drug designed to block blood clot formation showed no major adverse effects in people with stable coronary artery disease, according to a report in todays rapid access issue of Circulation: Journal of the American Heart Association.

The compound, DX-9065a, inhibits the action of factor Xa, one of the thirteen known factors involved in forming blood clots in coronary arteries. Factor Xa activates an enzyme called thrombin, which promotes the conversion of fibrinogen into fibrin, a major component of blood clots.

This is the first clinical experience with a direct, selective, reversible factor Xa inhibitor in patients with coronary artery disease, says cardiology researcher Robert A. Harrington, M.D., of the Duke Clinical Research Institute, in Durham, N.C. Our findings should lay the groundwork for further investigation of this and other agents that inhibit factor Xa in people with atherothrombosis, ischemic heart disease, and those undergoing coronary bypass surgery.

Anticoagulants, or blood-thinning drugs, work by inhibiting the ability of the blood to clot. Blood clots lodged in the coronary arteries block blood flow to the heart and cause most heart attacks. Anticoagulant therapy is commonly prescribed for people with heart disease to prevent further clot formation. The biggest drawback for anticoagulant drugs has been the potential for bleeding complications The randomized, double blind, placebo-controlled study, dubbed XaNADU, involved 73 patients with stable coronary artery disease at 10 medical centers. Their median age was 63 years, and 29 percent were women. Most had suffered a prior heart attack or had undergone angioplasty or coronary artery bypass surgery. During the study, 15 patients received a placebo, while 58 people received one of four different doses of DX-9065a, administered continuously over 72 hours.

Incidence of bleeding was minor and usually around the inf

Contact: Carole Bullock
American Heart Association

Page: 1 2

Related medicine news :

1. Chemical cousin of anti-anxiety drugs holds promise for psoriasis treatment
2. Direct payments to households in poor countries could improve maternal & child health
3. Worlds largest scientific society holds regional meeting Sept. 29 - Oct. 2 in Fort Worth
4. Case Western Reserves Flight Nursing Academy holds camp for nurses in air medical services
5. Optical glucose sensor holds promise for diabetics and intensive care patients
6. Intl Assoc for Dental Research holds 83rd General Session
7. Blood-diverting catheter holds promise for stroke treatment
8. Overweight and obesity thresholds may be misleading for Asian populations
9. Baclofen holds promise for cocaine treatment
10. Study shows combining gene therapy and radiation holds promise
11. Drug holds promise as an alternative for sickle cell patients unable to tolerate standard treatment

Post Your Comments:

(Date:10/12/2017)... ... , ... Leading pediatric oncology experts at Children’s National Health System ... of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. Chaired by ... Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., Chief of the ...
(Date:10/12/2017)... Mich. (PRWEB) , ... October 12, 2017 , ... ... has been named one of Michigan’s 2017 Best and Brightest in Wellness® by ... Brightest in Wellness® awards program on Friday, Oct. 20 from 7:30 a.m. to ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... in property taxes a year. In some states—like New York, New Jersey, Massachusetts, ... contrast, many overseas retirement havens have extremely low property-tax rates, which contributes to ...
(Date:10/12/2017)... ... October 12, 2017 , ... Farm Forward joins ... other leading institutions in announcing the launch of the Leadership Circle , ... animals are raised for food. , Founding members of the Leadership Circle also ...
(Date:10/12/2017)... ... 12, 2017 , ... Nvision Biomedical Technologies , a ... addition of industry sales leader, Thomas (Tom) Slott, as Senior Vice President of ... sales network, direct the efforts of the surgical sales teams, manage contractual agreements, ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... , Oct. 2, 2017  AllianceRx Walgreens Prime, the ... by Walgreens and pharmacy benefit manager Prime Therapeutics LLC ... brand, which included the unveiling of new signage at ... as well as at a few other company-owned facilities ... brand to patients, some of whom will begin to ...
(Date:9/28/2017)... Hill-Rom Holdings, Inc. (NYSE: HRC), will host its fiscal ... Friday, November 3, 2017, beginning at 7:00 a.m. (CDT) ... a.m. (CDT) / 9:30 a.m. (EDT). In ... guidance for 2018, Hill-Rom executives will also highlight the ... long-range financial outlook through 2020. ...
(Date:9/27/2017)... and NEW YORK , Sept. 27, 2017 ... mobile health and big data solutions, today announced that its MyDario product ... check your local TV listings for when The Dr. Oz Show airs ... The ... this month. ...
Breaking Medicine Technology:
Cached News: